Biopharma buffers offer stable pH levels required for the production and storage of biologics and help maintain integrity of the molecules. These buffers facilitate cell growth and minimize stress-related reactions. Need for advanced biologics for treatment of chronic diseases is driving demand for biopharma buffers.
Market key trends:
The increased demand for biologics is one of the major trends in the biopharma buffer market. Biologics have revolutionized treatment for various chronic diseases. Moreover, development of advanced biotherapeutics such as monoclonal antibodies, recombinant proteins, and gene therapies have increased the demand for biopharma buffers. As biologics production involves sensitive biological processes, stable pH levels and ion concentrations are crucial throughout various stages including cell culture, purification, and storage. Biopharma buffers help maintain integrity and efficacy of biologics. Growing biopharmaceutical industry and rising preference for biologics over small molecules drugs will continue to accelerate demand for biopharma buffers over the forecast period.
Segment Analysis
The biopharma buffer market is segmented based on product type, storage form, application, and end user. Based on product type, the market for pharmaceutical buffers is dominated by phosphate buffer solutions segment due to its ability to maintain pH during various processing stages such as purification, stabilization and formulation of biologics. Based on storage form, the liquid buffer solutions dominates the market as it is widely utilized for its ease of handling and adjusting of pH during different stages of biotherapeutic development and manufacturing processes.
Key Takeaways
The Global Biopharma Buffer Market Demand is expected to witness high growth. The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 billion in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030.
Regional analysis related content comprises the North American region dominates the biopharma buffer market currently due to presence of large number of pharmaceutical and biotech companies and expanding biosimilars industry in the region. Europe is the second largest market for biopharma buffers market owing to supportive regulatory environment and increasing R&D investment in novel biologic drug development.
Key players related content comprises Key players operating in the biopharma buffer market are Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE Healthcare, Promega Corporation, Hamilton Company, XZHB BIOTECH CO. These players are focusing on new product launches and expansion of regional presence to strengthen their market position.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/biopharma-buffer-market-share-and-demand-analysis/
Explore more trending article related this topic -
Comments
0 comment